Clinical trials: Skin Tumors
Metastatic Breast Cancer
Clinical Value of 89Zr-trastuzumab PET
Information about the presence of human epidermal growth factor receptor 2 (HER2) in tumor lesions in breast cancer patients is essential for diagnostic and therapeutic management of metastatic breast cancer.
- Trial name
- NCT01832051
- Testing
- 89Zr-trastuzumab injection
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Breast Cancer
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00971737
- Testing
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast
Although approximately 50% of new diagnosis breast cancers are in patients above the age of 65, elderly people remain substantially under-represented in clinical trials, and therefore are under-treated.
- Trial name
- ICE-II (NCT01204437)
- Testing
- Epirubicin, Cyclophosphamide, Cyclophosphamide, Methotrexate, 5 FU, Capecitabine, Nab-Paclitaxel
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- GBG Forschungs GmbH
Breast Tumor
Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer
Major Aims of study: 1. To create a gene expression-based prognostic device that complements or exceeds the prognostic utility of conventional biomarkers of breast cancer outcome. 2.
- Trial name
- NCT01247480
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Breast Cancer
Impact of Adapted Physical Activity on Cognitive Functions in Breast Cancer
Breast cancer is the most frequent cancer in women in western countries. The improvement of therapeutic management associated to the developement of supportive care allows patient to live longer in better conditions.
- Trial name
- COG-SPORTIF (NCT02934880)
- Testing
- immediate APA program, delayed APA program
- Where
- 3 sites in France
- Volunteers
- 37 people
- Sponsor
- Centre Henri Becquerel
Basal Cell Carcinoma of Skin, Optical Coherence Tomography (OCT)
Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice
Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by…
- Conditions
- Basal Cell Carcinoma of Skin, Optical Coherence Tomography (OCT), Neoplasms, Neoplasms, Basal Cell
- Trial name
- RELI (NCT07501780)
- Where
- Netherlands
- Volunteers
- 297 people
- Sponsor
- Maastricht University Medical Center
Colorectal Cancer, Breast Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in…
- Conditions
- Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer
- Trial name
- NCT04640480
- Testing
- SNB-101
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- SN BioScience
Breast Cancer
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
This study will evaluate the efficacy and safety of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) in participants with metastatic breast cancer who have progressed on trastuzumab-based therapy (Cohorts 1 and…
- Trial name
- NCT01674062
- Testing
- Pertuzumab, Trastuzumab
- Where
- 20 sites in Canada, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
AMTEC IIT: Phase 2 Multiarm Study in TNBC
This phase II study assesses the efficacy of the combination of olaparib with durvalumab, selumetinib, or capivasertib or ceralasertib alone in the treatment of patients with metastatic triple negative breast cancer (TNBC).
- Trial name
- NCT03801369
- Testing
- Biopsy, Capivasertib, Ceralasertib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Gordon Mills, MD, PhD
Breast Cancer, Prostate Cancer
Redes III Patient Navigator Qol Study
This proposed 5-year Redes En Acción research study involves a mixed-methods approach that occurs in two phases across two distinct and diverse HL communities.
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT02275754
- Testing
- PN+LCNC, PN Only
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metastatic Breast Cancer
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
This is an open-label phase Ib multi-institution trial that evaluates the safety profile/tolerability and preliminary anti-tumor effect of BKM120 (a PI3K inhibitor) and endocrine therapy combination and BEZ235 (a PI3K/ mTOR…
- Trial name
- NCT01248494
- Testing
- BEZ235, BKM 120, Letrozole
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Melanoma
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease.
- Trial name
- NCT01340729
- Testing
- TPI 287
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer after failing other treatments.
- Trial name
- ICE (NCT01097642)
- Testing
- Cetuximab, Ixabepilone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer, Non Small Cell Lung Cancer
Minimal Residual Disease in Solid Malignancies
The IMRD study is a single-centre, prospective observational study which will investigate the rate of ctDNA (circulating tumor DNA) detection from the start of adjuvant therapy following curative-intent surgery.
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer, High Grade Serous Ovarian Cancer
- Trial name
- IMRD (NCT07268469)
- Testing
- ctDNA detection
- Volunteers
- 840 people
- Sponsor
- European Institute of Oncology
Ovarian Carcinoma, Breast Cancer
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
This is a Phase II, open label, non randomized correlative study of AZD2281 in patients with recurrent breast and ovarian cancer in both BRCA inherited mutation carriers and non-carriers to identify objective response rate and to…
- Trial name
- NCT00679783
- Testing
- AZD2281
- Where
- 6 sites in Canada
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Lung Cancer, Breast Cancer
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion
This is a prospective, open-label , multicenter randomized controlled trial, with 248 cases in 50 centers planned for a period of 2 years.
- Conditions
- Lung Cancer, Breast Cancer, Malignant Pleural Effusion
- Trial name
- NCT04131231
- Testing
- microparticles packaging methotrexate (MPs-MTX), recombinant human interleukin-2(rhIL-2)
- Volunteers
- 248 people
- Sponsor
- Peking Union Medical College
Melanoma
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or…
- Trial name
- COLUMBUS (NCT01909453)
- Testing
- LGX818, MEK162, vemurafenib
- Where
- 282 sites in United States, Argentina and 27 more
- Volunteers
- 921 people
- Sponsor
- Pfizer
Metastatic Melanoma
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells
This protocol was conducted as a single institution trial at Hoag Cancer Center, Hoag Hospital, Newport Beach, California. It was a single-arm phase II trial in which patients with metastatic melanoma received subcutaneous (s.c.)…
- Trial name
- DCVaccineMel (NCT00948480)
- Testing
- Autologous tumor cells plus dendritic cells, GM-CSF
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma
Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
This study evaluates how useful and acceptable the components of the "Couples Coping Together Against Cancer", referred to as "The Program", are to the participants with cancer.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT07664579
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center